21.9.2026, 13:18
Emergen Research, a prominent provider of market research solutions, has announced the launch of its much-awaited suite of comprehensive market research content. This new offering is designed to equip businesses across various industries with actionable insights and data-driven strategies to support growth and long-term success.
Request a free sample copy to understand the complete structure of this report (including summary and table of contents) @ https://www.emergenresearch.com/request-...mple/14951
The Cell & Gene Therapy Contract Research Organizations Market was valued at USD 8.2 billion in 2024 and is projected to reach USD 24.7 billion by 2034, registering a CAGR of 11.6%. Market revenue growth is driven by factors such as increasing regulatory approvals for cell and gene therapies, rising investment in advanced therapeutic research, and growing demand for specialized outsourcing services among biopharmaceutical companies.
The therapeutic landscape has witnessed unprecedented momentum with gene and cell therapy approvals accelerating across major regulatory jurisdictions. According to the US Food and Drug Administration (FDA), over 40 cell and gene therapy products have received approval since 2017, with the agency projecting 10-20 new approvals annually through 2025. This regulatory momentum creates substantial demand for specialized contract research organizations capable of navigating complex development pathways.
Investment patterns reveal strong institutional confidence in the sector. The National Institutes of Health (NIH) allocated USD 2.8 billion towards gene therapy research in fiscal year 2024, representing a 15% increase from the previous year. Private sector investment has similarly intensified, with venture capital funding for cell and gene therapy companies reaching USD 12.4 billion globally in 2024, according to data from the Organization for Economic Co-operation and Development (OECD).
Manufacturing complexity drives significant outsourcing demand. Cell and gene therapies require specialized facilities, advanced analytics, and regulatory expertise that many biotechnology companies lack internally. The World Health Organization (WHO) estimates that establishing in-house manufacturing capabilities for cell therapies requires USD 50-100 million in initial capital investment, making outsourcing economically attractive for emerging companies.
Growth is underpinned by expanding therapeutic applications beyond oncology into rare diseases, ophthalmology, and neurology. The European Medicines Agency (EMA) reported that 60% of advanced therapy medicinal products in development target non-oncology indications, broadening the addressable patient population and market opportunity.
Geographic expansion contributes to market dynamics, with Asia-Pacific emerging as a key growth region. Countries like Japan, South Korea, and Singapore have established regulatory frameworks encouraging cell and gene therapy development, creating demand for regional CRO services with local expertise.
Competitive Landscape
Key players operating in the global cell and gene therapy contract research organizations market are undertaking various initiatives to strengthen their presence and expand their service capabilities. Strategies such as facility expansions, strategic partnerships, and technology acquisitions are driving market growth and enhancing service delivery capabilities.
Key Global Cell & Gene Therapy CRO Companies:
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- Charles River Laboratories International, Inc.
- WuXi AppTec Co., Ltd.
- Catalent, Inc.
- IQVIA Holdings Inc.
- Parexel International Corporation
- PPD, Inc. (Thermo Fisher Scientific)
- SGS SA
- Eurofins Scientific SE
At Emergen Research, our mission is to empower businesses with the knowledge and insights needed to make informed decisions and succeed in today's dynamic market environment. Our research content is crafted to provide professionals and organizations with in-depth analysis, actionable recommendations, and a competitive advantage to support their growth objectives.
Custom requirements can be requested for this report, with customization options available to suit specific business needs @ https://www.emergenresearch.com/request-...tion/14951
Key highlights and advantages of the market research content offered by Emergen Research include:
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Sales Specialist
Emergen Research | Website: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
Email: sales@emergenresearch.com
Request a free sample copy to understand the complete structure of this report (including summary and table of contents) @ https://www.emergenresearch.com/request-...mple/14951
The Cell & Gene Therapy Contract Research Organizations Market was valued at USD 8.2 billion in 2024 and is projected to reach USD 24.7 billion by 2034, registering a CAGR of 11.6%. Market revenue growth is driven by factors such as increasing regulatory approvals for cell and gene therapies, rising investment in advanced therapeutic research, and growing demand for specialized outsourcing services among biopharmaceutical companies.
The therapeutic landscape has witnessed unprecedented momentum with gene and cell therapy approvals accelerating across major regulatory jurisdictions. According to the US Food and Drug Administration (FDA), over 40 cell and gene therapy products have received approval since 2017, with the agency projecting 10-20 new approvals annually through 2025. This regulatory momentum creates substantial demand for specialized contract research organizations capable of navigating complex development pathways.
Investment patterns reveal strong institutional confidence in the sector. The National Institutes of Health (NIH) allocated USD 2.8 billion towards gene therapy research in fiscal year 2024, representing a 15% increase from the previous year. Private sector investment has similarly intensified, with venture capital funding for cell and gene therapy companies reaching USD 12.4 billion globally in 2024, according to data from the Organization for Economic Co-operation and Development (OECD).
Manufacturing complexity drives significant outsourcing demand. Cell and gene therapies require specialized facilities, advanced analytics, and regulatory expertise that many biotechnology companies lack internally. The World Health Organization (WHO) estimates that establishing in-house manufacturing capabilities for cell therapies requires USD 50-100 million in initial capital investment, making outsourcing economically attractive for emerging companies.
Growth is underpinned by expanding therapeutic applications beyond oncology into rare diseases, ophthalmology, and neurology. The European Medicines Agency (EMA) reported that 60% of advanced therapy medicinal products in development target non-oncology indications, broadening the addressable patient population and market opportunity.
Geographic expansion contributes to market dynamics, with Asia-Pacific emerging as a key growth region. Countries like Japan, South Korea, and Singapore have established regulatory frameworks encouraging cell and gene therapy development, creating demand for regional CRO services with local expertise.
Competitive Landscape
Key players operating in the global cell and gene therapy contract research organizations market are undertaking various initiatives to strengthen their presence and expand their service capabilities. Strategies such as facility expansions, strategic partnerships, and technology acquisitions are driving market growth and enhancing service delivery capabilities.
Key Global Cell & Gene Therapy CRO Companies:
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- Charles River Laboratories International, Inc.
- WuXi AppTec Co., Ltd.
- Catalent, Inc.
- IQVIA Holdings Inc.
- Parexel International Corporation
- PPD, Inc. (Thermo Fisher Scientific)
- SGS SA
- Eurofins Scientific SE
At Emergen Research, our mission is to empower businesses with the knowledge and insights needed to make informed decisions and succeed in today's dynamic market environment. Our research content is crafted to provide professionals and organizations with in-depth analysis, actionable recommendations, and a competitive advantage to support their growth objectives.
Custom requirements can be requested for this report, with customization options available to suit specific business needs @ https://www.emergenresearch.com/request-...tion/14951
Key highlights and advantages of the market research content offered by Emergen Research include:
- Comprehensive Analysis: Each report is thoroughly researched and delivers an in-depth evaluation of market trends, competitive dynamics, consumer behavior, and emerging opportunities. This enables businesses to uncover untapped markets, develop effective strategies, and make well-informed, data-driven decisions.
- Actionable Recommendations: The content offers practical insights and clear, actionable recommendations to help organizations improve their products, services, and overall customer experience. These suggestions are tailored to specific industry needs, supporting sustainable growth and enhanced profitability.
- Expert Insights: Backed by a team of experienced analysts, Emergen Research provides valuable perspectives on industry challenges, best practices, and upcoming trends, helping businesses stay competitive and capitalize on new opportunities.
- Timely Updates: The research content is consistently updated to reflect the latest market developments. Subscribers gain access to current and relevant insights, allowing them to adapt quickly and remain competitive in a rapidly changing business landscape.
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Sales Specialist
Emergen Research | Website: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
Email: sales@emergenresearch.com